

Tel: + 34 91 244 44 10


AWARD OF A GRANT FOR TRAINING ACTIONS FOR THE QUALIFICATION AND REQUALIFICATION OF THE PERSONNEL OF ROVI PHARMA INDUSTRIAL SERVICES, S.A.

Madrid -29December 2022

ROVI PHARMA INDUSTRIAL SERVICES, S.A. has been the beneficiary of a grant to carry out training actions for qualification and requalification of the active population, linked to professional qualifications in strategic sectors within the framework of the RECOVERY, TRANSFORMATION AND RESILIENCE PLAN - FINANCED BY THE EUROPEAN UNION – NEXT GENERATION EU, and managed by the MINISTRY OF ECONOMY, FINANCE and EMPLOYMENT OF the COMMUNITY OF MADRID.

The aid granted will allow 7 training actions for a total of 375 workers, throughout the 2022 and 2023 annuities; Specifically, ROVI PHARMA INDUSTRIAL SERVICES plans to conduct four training actions for 228 workers in 2022 and 3 training actions for 147 workers in 2023.

The amount of the approved grant was €137,250.00, with file number CR8-07/2022/5372EMP.









Training actions financed by the Ministry of Economy, Finance and Employment with the funds transferred by the Ministry of Education and Vocational Training

About

ROVI is a pan-European pharmaceutical company, specialized and dedicated to the research, development, licensed manufacturing and commercialization of small molecules and biological specialties. The company, in continuous process of international expansion, has subsidiaries in Portugal, Germany, United Kingdom, Italy, France and Poland, and has a diversified portfolio of more than 40 marketed products, in which its reference product, Bemiparin, stands out, which is already marketed in 56 countries around the world. Likewise, in 2017, ROVI began marketing its internally developed Enoxaprine biosimilar in Europe. ROVI continues to develop the technology of the ISM® Platform, a leading line of research in the field of extended release of drugs with proven advantages. For more information visit www.rovi.es.